Prognostic Associations of Activated Mitogen-Activated Protein Kinase and Akt Pathways in Glioblastoma
暂无分享,去创建一个
Li Zhang | Susan Chang | Howard Colman | Dima Suki | Susan M. Chang | K. Aldape | W. Yung | M. Prados | G. Fuller | H. Colman | C. Pelloski | A. Heimberger | Juinn-Lin Liu | D. Suki | Kenneth D. Aldape | W.K. Alfred Yung | Michael Prados | Gregory N. Fuller | Amy B. Heimberger | E Lin | Christopher E. Pelloski | Juinn-Lin Liu | Shaio Y. Woo | Fredrick G. Barker | Li Zhang | E. Lin | Shaio Y Woo | F. G. Barker | Juinn-lin Liu
[1] D. Nelson,et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.
[2] M. Prados,et al. Radiation response and survival time in patients with glioblastoma multiforme. , 1996, Journal of neurosurgery.
[3] A. Pawson,et al. Proliferation of human malignant astrocytomas is dependent on Ras activation , 1997, Oncogene.
[4] W. Curran,et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. , 1998, International journal of radiation oncology, biology, physics.
[5] P. Forsyth,et al. Long-term Glioblastoma Multiforme Survivors: a Population-based Study , 1998, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[6] M. Prados,et al. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors. , 1998, International journal of radiation oncology, biology, physics.
[7] M. Sant,et al. Survival rates for primary malignant brain tumours in Europe. EUROCARE Working Group. , 1998, European journal of cancer.
[8] F. Lang,et al. Radiosensitization of human tumor cell lines induced by the adenovirus-mediated expression of an anti-Ras single-chain antibody fragment. , 1999, Cancer research.
[9] S. Altschul,et al. A public database for gene expression in human cancers. , 1999, Cancer research.
[10] D. Vordermark,et al. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. , 2000, Anticancer research.
[11] P. Dent,et al. Inhibition of the mitogen activated protein kinase pathway potentiates radiation-induced cell killing via cell cycle arrest at the G2/M transition and independently of increased signaling by the JNK/c-Jun pathway. , 2000, International journal of oncology.
[12] Susan M. Chang,et al. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. , 2001, International journal of radiation oncology, biology, physics.
[13] M. Berger,et al. EGFR overexpression and radiation response in glioblastoma multiforme. , 2001, International journal of radiation oncology, biology, physics.
[14] Keiji Suzuki,et al. Extremely low-dose ionizing radiation causes activation of mitogen-activated protein kinase pathway and enhances proliferation of normal human diploid cells. , 2001, Cancer research.
[15] Susan M. Chang,et al. Glioblastoma Patients Epidermal Growth Factor Receptor , and Survival in Analysis of Complex Relationships between Age , p 53 , Updated , 2001 .
[16] S. Gullans,et al. Differential gene expression profiling in human brain tumors. , 2001, Physiological genomics.
[17] R. Muschel,et al. The Ras radiation resistance pathway. , 2001, Cancer research.
[18] C. Gondi,et al. Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro , 2002, Oncogene.
[19] M Hareyama,et al. MEK/ERK pathway protects ionizing radiation-induced loss of mitochondrial membrane potential and cell death in lymphocytic leukemia cells , 2002, Cell Death and Differentiation.
[20] James R. Van Brocklyn,et al. Sphingosine-1-phosphate stimulates human glioma cell proliferation through Gi-coupled receptors: role of ERK MAP kinase and phosphatidylinositol 3-kinase β , 2002 .
[21] Mark R Gilbert,et al. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. , 2002, Cancer research.
[22] C. Rhee,et al. Modulation of phorbol ester-induced regulation of matrix metalloproteinases and tissue inhibitors of metalloproteinases by SB203580, a specific inhibitor of p38 mitogen-activated protein kinase. , 2002, Journal of neurosurgery.
[23] H. Ling,et al. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. , 2002, The Biochemical journal.
[24] H. Rodemann,et al. Early growth response-1 gene (Egr-1) promoter induction by ionizing radiation in U87 malignant glioma cells in vitro. , 2002, European journal of biochemistry.
[25] Brett L Carlson,et al. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. , 2002, Cancer research.
[26] N. Socci,et al. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. , 2003, Molecular cell.
[27] Alfonso Bellacosa,et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. , 2003, Cancer research.
[28] V. Kavsan,et al. HC gp-39 gene is upregulated in glioblastomas. , 2003, Cancer letters.
[29] Siegfried Kropf,et al. Prognostic relevance of MAPK expression in glioblastoma multiforme. , 2003, International journal of oncology.
[30] Paul S Mischel,et al. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. , 2003, Cancer research.
[31] E. Shaw,et al. Reexamining the radiation therapy oncology group (RTOG) recursive partitioning analysis (RPA) for glioblastoma multiforme (GBM) patients , 2003 .
[32] S. Pinder,et al. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome , 2004, The Journal of pathology.
[33] T. Nonaka,et al. Selective inhibition of survival signal transduction pathways enhanced radiosensitivity in human esophageal cancer cell lines in vitro. , 2004, Anticancer research.
[34] Alona Muzikansky,et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] J. Soh,et al. PKC-η mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways , 2004, Oncogene.
[36] V. A. Flørenes,et al. Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. , 2005, American journal of clinical pathology.
[37] B. Scheithauer,et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] K. Aldape,et al. YKL-40 Expression is Associated with Poorer Response to Radiation and Shorter Overall Survival in Glioblastoma , 2005, Clinical Cancer Research.
[39] K. Aldape,et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. , 2005, Cancer research.
[40] M. Berger,et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. , 2005, Journal of the National Cancer Institute.